Disc Medicine Advances DISC-3405 in Polycythemia Vera
WATERTOWN, Mass. — September 9, 2026 Disc Medicine, Inc. presented positive initial results from the Phase 2 RESTORE-PV trial...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WATERTOWN, Mass. — September 9, 2026 Disc Medicine, Inc. presented positive initial results from the Phase 2 RESTORE-PV trial...
New York, New York, August 20, 2026 Nuvation Bio Inc. has announced that the U.S. Food and Drug Administration...
Silver Spring, Maryland, August 19, 2026 The U.S. Food and Drug Administration (FDA) has authorized Aletta, a first-of-its-kind standalone...
